.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Medtronic
Accenture
Teva
Cipla
Julphar
McKinsey
US Army
Johnson and Johnson
Citi

Generated: September 24, 2017

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?

ALLERGAN has one hundred and one approved drugs.

There are one hundred and twenty US patents protecting ALLERGAN drugs on ALLERGAN drugs in the past three years.

There are seven hundred and eighty-four patent family members on ALLERGAN drugs in forty-four countries.

Summary for Applicant: Allergan

Patents:120
Tradenames:86
Ingredients:64
NDAs:101
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
INFED
iron dextran
INJECTABLE;INJECTION017441-001Approved Prior to Jan 1, 1982BPRXYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
NORINYL 1+35 28-DAY
ethinyl estradiol; norethindrone
TABLET;ORAL-28017565-002Approved Prior to Jan 1, 1982ABRXNoNo► Subscribe► Subscribe► Subscribe
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021770-001Aug 19, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
OCUFEN
flurbiprofen sodium
SOLUTION/DROPS;OPHTHALMIC019404-001Dec 31, 1986ATRXYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
OCUFEN
flurbiprofen sodium
SOLUTION/DROPS;OPHTHALMIC019404-001Dec 31, 1986► Subscribe► Subscribe
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-001Sep 29, 1995► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-004Apr 5, 2002► Subscribe► Subscribe
Allergan Sales Llc
TRELSTAR
triptorelin pamoate
INJECTABLE;INTRAMUSCULAR020715-001Jun 15, 2000► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-003Dec 20, 1996► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996► Subscribe► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-001Dec 20, 1996► Subscribe► Subscribe
Allergan
ZYMAR
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC021493-001Mar 28, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN drugs

Drugname Dosage Strength Tradename Submissiondate
dapsone
Gel7.5%
ACZONE
2/13/2017
alcaftadine
Ophthalmic Solution0.25%
LASTACAFT
7/30/2014
oxybutynin chloride
Gel10%
GELNIQUE
6/19/2014
milnacipran hydrochloride
Tablets12.5 mg, 25 mg, 50 mg, and 100 mg
SAVELLA
1/14/2013
silodosin
Capsules4 mg and 8 mg
RAPAFLO
10/9/2012
ketorolac tromethamine
Opthalmic Solution0.45%
ACUVAIL
8/24/2011
ketorolac tromethamine
Opthalmic Solution0.45%
ACUVAIL
8/23/2011
bimatoprost
Ophthalmic Solution0.01%
LUMIGAN
4/5/2011
gatifloxacin
Ophthalmic Solution0.5%
ZYMAXID
12/7/2010
bimatopros
Topical Solution0.03%
LATISSE
5/3/2010
trospium chloride
Extended-release Capsules60 mg
SANCTURA XR
3/2/2009
bimatoprost
Ophthalmic Solution0.03%
LUMIGAN
12/22/2008
brimonidine tartrate and timolol maleate
Ophthalmic Solution0.2%/0.5%
COMBIGAN
11/21/2008
epinastine hydrochloride
Ophthalmic Solution0.05%
ELESTAT
10/14/2008
oxybutynin
Transdermal System Extended-re3.9 mg/24 hrs
OXYTROL
8/19/2008
gatifloxacin
Ophthalmic Solution0.30%
ZYMAR
7/19/2007
brimonidine tartrate
Ophthalmic Solution0.10%
ALPHAGAN P
12/20/2006
brimonidine tartrate
Ophthalmic Solution0.15%
ALPHAGAN P
11/3/2006
ketorolac tromethamine
Ophthalmic Solution0.40%
ACULAR LS
1/28/2005

Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
8,048,445Ocular implant made by a double extrusion process► Subscribe
8,859,604Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
7,388,029Compositions and methods for treating hair loss using non-naturally occurring prostaglandins► Subscribe
8,877,793Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists► Subscribe
7,214,381Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
8,071,120Methods for treating neovascularization and intravitreal implants► Subscribe
8,980,309Transdermal testosterone formulation for minimizing skin residues► Subscribe
8,318,070Ocular implant made by a double extrusion process► Subscribe
7,915,246Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Drugs

Country Document Number Estimated Expiration
Norway20080055► Subscribe
Japan2014043451► Subscribe
Hong Kong1203839► Subscribe
South Korea20120030078► Subscribe
World Intellectual Property Organization (WIPO)2012075319► Subscribe
World Intellectual Property Organization (WIPO)2005090315► Subscribe
Germany602004023516► Subscribe
Cyprus1118431► Subscribe
Canada2474280► Subscribe
Japan2010168119► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
12/018Ireland► SubscribePRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
C/GB98/002United Kingdom► SubscribePRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
C0005Belgium► SubscribePRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
C/GB01/014United Kingdom► SubscribePRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Merck
Accenture
Chubb
Johnson and Johnson
AstraZeneca
Chinese Patent Office
Dow
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot